Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Telix Pharmaceuticals Ltd Capital/Financing Update 2017

Nov 14, 2017

31324_rns_2017-11-14_ba8da29d-93b8-4a55-8ac4-6728fd4916d6.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Notice

Notice reference number: tbc

Notice date: 15/11/2017

What’s this about?

Effective date: 15/11/2017

==> picture [505 x 89] intentionally omitted <==

----- Start of picture text -----

 ASX Trade ASX 24 ASX TECH
 Trading Clearing Settlement ALC ASX NET
Operations Technology Market Data Rules Compliance Risk  Other
----- End of picture text -----

Title

Telix Pharmaceuticals Limited – Admission and Commencement of Official Quotation - Update

Description

Further to the ASX Notice released on 14 November 2017, ASX now confirms as follows.

Telix Pharmaceuticals Limited (Company) was admitted to the Official List of ASX today, Wednesday 15 November 2017.

Official quotation of the Company’s securities will commence at 12:00 pm AEDT on Wednesday, 15 November 2017 on a deferred settlement basis. The Company has raised $50.05 million by the offer of 77,000,000 ordinary shares at $0.65 per share under a prospectus dated 16 October 2017.

What do I need to do and by when?

For further details, please refer to the Company’s prospectus dated 16 October 2017.

Need more information?

For further details, please refer to the Company’s prospectus dated 16 October 2017.

Issued by James Gerraty

4B

Contact Details

(03) 9617 7842

5

Disclaimer

1/1